CRSP News and Press, CRISPR Therapeutics AG From 06/07/24

2024-06-07 18:26:03 ET Summary The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered along with Enovix, Uranium Royalty, Clover Health, a...

2024-06-06 00:40:07 ET CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants Maury Raycroft - Jefferies Presentatio...

2024-06-05 07:11:15 ET Summary Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering potential treatments for genetic diseases. Robust t...

2024-06-04 06:45:00 ET Via her ARK Innovation ETF (NYSEMKT: ARKK) , portfolio manager Cathie Wood makes a lot of biotech bets, often on companies that are at the cutting edge of innovation in science and technology. Businesses like that tend to have volatile and temperamental stocks...

2024-06-03 01:35:02 ET Summary CRISPR's gene therapy, Casgevy, faces operational challenges and stiff competition from Lyfgenia, impacting its market adoption. The initial commercial rollout of gene therapies requires the establishment of authorized treatment centers, and CRISPR h...

2024-05-30 13:54:38 ET More on biolinerx BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on biolinerx Historical earnings data for biolinerx Financial in...

2024-05-27 12:32:15 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let’s get some of the bad st...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

2024-05-23 11:48:35 ET Summary Nkarta, Inc. has raised $240.1 million through a stock offering, strengthening its cash position and extending its cash runway to 2027. The company's stock has been trending down, but there are signs of recovery, with a 6.4% increase in share price. ...

2024-05-23 08:26:07 ET More on CRISPR Therapeutics CRISPR Therapeutics AG (CRSP) BofA Securities 2024 Health Care Conference (Transcript) Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg Crispr Therapeutics: Market Misunderstanding Is Your ...